Mostrar el registro sencillo del ítem

dc.contributor.authorFernández-Ruiz, Mario
dc.contributor.authorAlmendro-Vázquez, Patricia
dc.contributor.authorCarretero, Octavio
dc.contributor.authorRuiz-Merlo, Tamara
dc.contributor.authorLaguna-Goya, Rocío
dc.contributor.authorSan Juan, Rafael
dc.contributor.authorLópez-Medrano, Francisco
dc.contributor.authorGarcia-Rios, Estefani 
dc.contributor.authorMas-Lloret, Vicente 
dc.contributor.authorMoreno-Batenero, Miguel
dc.contributor.authorLoinaz, Carmelo
dc.contributor.authorAndrés, Amado
dc.contributor.authorPerez-Romero, Pilar 
dc.contributor.authorPaz-Artal, Estela
dc.contributor.authorAguado, José María
dc.contributor.authorOctavio
dc.date.accessioned2022-05-06T12:40:01Z
dc.date.available2022-05-06T12:40:01Z
dc.date.issued2021-11-17
dc.identifier.citationTransplant Direct 2021 Nov 17;7(12):e794.es_ES
dc.identifier.issn2373-8731es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/14309
dc.description.abstractBackground: Severe acute respiratory syndrome coronavirus 2-specific cell-mediated immunity (SARS-CoV-2-CMI) elicited by mRNA-based vaccines in solid organ transplant (SOT) recipients and its correlation with antibody responses remain poorly characterized. Methods: We included 44 (28 kidney, 14 liver, and 2 double organ) recipients who received the full series of the mRNA-1273 vaccine. SARS-CoV-2-CMI was evaluated at baseline, before the second dose, and at 2 wk after completion of vaccination by an ELISpot-based interferon-γ FluoroSpot assay using overlapping peptides covering the S1 domain. SARS-CoV-2 immunoglobulin G seroconversion and serum neutralizing activity against the spike protein were assessed at the same points by commercial ELISA and an angiotensin-converting enzyme-2/spike antibody inhibition method, respectively. Postvaccination SARS-CoV-2-CMI was compared with 28 healthcare workers who received the BNT162b2 vaccine. Results: Positive SARS-CoV-2-CMI increased from 6.8% at baseline to 23.3% after the first mRNA-1273 dose and 59.5% after the completion of vaccination (P < 0.0001). Lower rates were observed for immunoglobulin G seroconversion (2.3%, 18.6%, and 57.1%, respectively) and neutralizing activity (2.3%, 11.6%, and 31.0%). There was a modest correlation between neutralizing titers and the magnitude of SARS-CoV-2-CMI (Spearman's rho: 0.375; P = 0.015). Fifteen recipients (35.7%) mounted SARS-CoV-2-CMI without detectable neutralizing activity, whereas 3 (7.1%) did the opposite, yielding poor categorical agreement (Kappa statistic: 0.201). Rates of positive SARS-CoV-2-CMI among SOT recipients were significantly decreased compared with nontransplant controls (82.1% and 100.0% after the first dose and completion of vaccination, respectively; P < 0.0001). Kidney transplantation, the use of tacrolimus and prednisone, and the number of immunosuppressive agents were associated with lower cell-mediated responses. Results remained unchanged when 3 recipients with prevaccination SARS-CoV-2-CMI were excluded. Conclusions: Two-thirds of SOT recipients mounted SARS-CoV-2-CMI following vaccination with mRNA-1273. Notable discordance was observed between vaccine-induced cell-mediated and neutralizing humoral immunities. Future studies should determine whether these patients with incomplete responses are effectively protected.es_ES
dc.description.sponsorshipThis work was supported by the Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation (COVID-19 Research Call COV20/00181) and cofinanced by the European Development Regional Fund “A way to achieve Europe.” M.F.R. holds a research contract “Miguel Servet” (CP18/00073) and R.L.G. a research contract “Rio Hortega” (CM19/00120), both from the Instituto de Salud Carlos III, Spanish Ministry of Science and Innovationes_ES
dc.language.isoenges_ES
dc.publisherLippincott Williams & Wilkins (LWW) es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.titleDiscordance Between SARS-CoV-2-specific Cell-mediated and Antibody Responses Elicited by mRNA-1273 Vaccine in Kidney and Liver Transplant Recipientses_ES
dc.typejournal articlees_ES
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.identifier.pubmedID34805496es_ES
dc.format.volume7es_ES
dc.format.number12es_ES
dc.format.pagee794es_ES
dc.identifier.doi10.1097/TXD.0000000000001246es_ES
dc.contributor.funderInstituto de Salud Carlos III es_ES
dc.contributor.funderMinisterio de Ciencia e Innovación (España) es_ES
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) es_ES
dc.description.peerreviewedes_ES
dc.relation.publisherversionhttps://doi.org/10.1097/TXD.0000000000001246es_ES
dc.identifier.journalTransplantation Directes_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES
dc.relation.projectFISinfo:fis/Instituto de Salud Carlos III/Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia/null/Contratos Miguel Servet (2018)/CP18/00073es_ES
dc.relation.projectFISinfo:fis/Instituto de Salud Carlos III/Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I/null/Contratos Río Hortega (2019)/CM19/00120es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/COV20/00181es_ES


Ficheros en el ítem

Acceso Abierto
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Este Item está sujeto a una licencia Creative Commons: Attribution-NonCommercial-NoDerivatives 4.0 Internacional